Halogenated rhodamine derivatives and applications thereof

Abstract

Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodmaine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. Examples of rhodamine compounds include 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4′, 5′-dichloro-benzoic acid methyl ester hydrochloride; 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide; acetate salt of 2,7-dibromorhodamine B hexyl ester; acetate salt of 2,7-dibromorhodamine B methyl ester; 4,5-dibromorhodamine 6G hydrobromide; rhodamine B 3-bromopropyl; acetate salt of 2,7-dibromo-4′-carboxytetramethylrosamine methyl ester; 4-bromo-5-phenyl rhodamine B methyl ester chloride; 2,7-dibromo-4,5-dimethyl rhodamine B methyl ester bromide; 2-bromo-7-ethynyl rhodamine B methyl ester bromide; and 4,5-dibromo-2,7-di-n-butyl rhodamine B methyl ester bromide.

1 . A method for treating a tissue sample from a patient, comprising the steps of:
 harvesting the tissue sample from the patient, wherein the tissue sample is infected with bacteria;   providing a rhodamine compound selected from the group consisting of 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4′,5′-dichloro-benzoic acid methyl ester hydrochloride; 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide; acetate salt of 2,7-dibromorhodamine B hexyl ester; acetate salt of 2,7-dibromorhodamine B methyl ester; 4,5-dibromorhodamine 6G hydrobromide; rhodamine B 3-bromopropyl; acetate salt of 2,7-dibromo-4′-carboxytetramethylrosamine methyl ester; 4-bromo-5-phenyl rhodamine B methyl ester chloride; 2,7-dibromo-4,5-dimethyl rhodamine B methyl ester bromide; 2-bromo-7-ethynyl rhodamine B methyl ester bromide; and 4,5-dibromo-2,7-di-n-butyl rhodamine B methyl ester bromide;   mixing the rhodamine compound and the tissue sample to form a mixture,   exposing the mixture to radiant energy to inhibit or kill the bacteria; and   transplanting the exposed mixture into the patient.   
     
     
         2 . The method of  claim 1 , wherein the bacteria is gram positive. 
     
     
         3 . The method of  claim 1 , wherein the bacteria is gram negative. 
     
     
         4 . The method of  claim 1 , wherein the bacteria is  Staphylococcus epidermitis.    
     
     
         5 . The method of  claim 1 , wherein the bacteria is at least one of  Escherichia coli  0157:H7 or  Salmonella thyphimurium , and wherein the rhodamine compound is 4,5-dibromo rhodamine 110 2-(2-methoxy ethoxy)ethyl ester. 
     
     
         6 . The method of  claim 1 , wherein the bacteria is  Salmonella thyphimurium  LT2, and wherein the rhodamine compound is the acetate salt of 2,7-dibromorhodamine B hexyl ester. 
     
     
         7 . The method of  claim 1 , wherein the bacteria is  Escherichia coli  0157:H7, and wherein the rhodamine compound is 4,5-dibromorhodamine 6G hydrobromide 
     
     
         8 . The method of  claim 1 , wherein the bacteria is  Escherichia coli  0157TH7, and wherein the compound is rhodamine B 3-bromopropyl ester. 
     
     
         9 . The method of  claim 1 , wherein the bacteria is selected from the group consisting of  Escherichia coli  0157TH7,  Salmonella thyphimurium  LT2, and  Pseudomonas aeruginosa , and wherein the rhodamine compound is 4,5-dibromorhodamine methyl ester. 
     
     
         10 . The method of  claim 1 , wherein the mixture is exposed to a wavelength of 514 nm. 
     
     
         11 . The method of  claim 1 , wherein the tissue sample is blood. 
     
     
         12 . The method of  claim 1 , wherein the tissue sample is bone marrow. 
     
     
         13 . The method of  claim 1 , wherein the mixture is exposed to radiant energy for 180 minutes. 
     
     
         14 . The method of  claim 1 , further comprising the steps of
 centrifuging the mixture:   resuspending the centrifuged mixture; and   incubating the resuspended centrifuged mixture.   
     
     
         15 . The method of  claim 14 , wherein the resuspended centrifuged mixture is incubated for 90 minutes. 
     
     
         16 . The method of  claim 14 , wherein the resuspended centrifuged mixture is incubated before exposing the mixture to radiant energy.